News
CTSO
0.3808
+5.19%
0.0188
Weekly Report: what happened at CTSO last week (0803-0807)?
Weekly Report · 1d ago
Cytosorbents Advances Toward Operating Cash Flow Breakeven
TipRanks · 3d ago
CytoSorbents: Neutral Rating Reiterated as Operational Progress Offsets Market and Regulatory Risks; $0.75 Price Target Maintained
TipRanks · 4d ago
Press Release: CytoSorbents Reports Second -3-
Dow Jones · 4d ago
Here are the major earnings after the close Thursday
Seeking Alpha · 5d ago
Weekly Report: what happened at CTSO last week (0727-0731)?
Weekly Report · 08/03 10:09
Weekly Report: what happened at CTSO last week (0720-0724)?
Weekly Report · 07/27 10:13
CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights
PR Newswire · 07/20 11:00
Weekly Report: what happened at CTSO last week (0713-0717)?
Weekly Report · 07/20 10:10
Weekly Report: what happened at CTSO last week (0706-0710)?
Weekly Report · 07/13 10:12
Cytosorbents Faces Nasdaq Compliance and Delisting Risk
TipRanks · 07/06 20:37
Weekly Report: what happened at CTSO last week (0629-0703)?
Weekly Report · 07/06 10:15
Weekly Report: what happened at CTSO last week (0622-0626)?
Weekly Report · 06/29 10:10
CytoSorbents Advances FDA Pathway for DrugSorb Programs
TipRanks · 06/25 13:48
Weekly Report: what happened at CTSO last week (0615-0619)?
Weekly Report · 06/22 10:19
Weekly Report: what happened at CTSO last week (0608-0612)?
Weekly Report · 06/15 10:20
Weekly Report: what happened at CTSO last week (0601-0605)?
Weekly Report · 06/08 10:15
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 06/04 12:05
Weekly Report: what happened at CTSO last week (0525-0529)?
Weekly Report · 06/01 10:20
Weekly Report: what happened at CTSO last week (0518-0522)?
Weekly Report · 05/25 10:23
More
Webull provides a variety of real-time CTSO stock news. You can receive the latest news about Cytosorbents Corp through multiple platforms. This information may help you make smarter investment decisions.
About CTSO
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.